Mission Statement, Vision, & Core Values (2024) of Immunic, Inc. (IMUX)

Mission Statement, Vision, & Core Values (2024) of Immunic, Inc. (IMUX)

US | Healthcare | Biotechnology | NASDAQ

Immunic, Inc. (IMUX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Immunic, Inc. (IMUX)

General Summary of Immunic, Inc. (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for chronic inflammatory and autoimmune diseases. The company was founded in 2016 and is headquartered in New York, NY.

Key Products and Pipeline

  • IMU-838 (vidofludimus calcium): Lead clinical-stage asset targeting inflammatory bowel disease and multiple sclerosis
  • IMU-856: Intestinal barrier restoration program
  • IMU-980: Selective oral BTK inhibitor for autoimmune diseases

Financial Performance (Q4 2023)

Financial Metric Amount
Cash and Cash Equivalents $123.4 million
Research and Development Expenses $32.7 million
Net Loss $41.2 million

Clinical Development Highlights

Current clinical trials in progress:

  • Phase 2 trial for IMU-838 in ulcerative colitis
  • Phase 2 trial for IMU-838 in multiple sclerosis
  • Phase 1 trial for IMU-856

Market Position

Immunic is positioned as an emerging biotechnology company with a focused pipeline in inflammatory and autoimmune disease therapeutics. The company has demonstrated potential through its innovative oral therapeutic approach and ongoing clinical development programs.

Stock Performance

Stock Metric Value
NASDAQ Ticker IMUX
52-Week Stock Price Range $3.25 - $8.45
Market Capitalization $230 million



Mission Statement of Immunic, Inc. (IMUX)

Mission Statement Overview

Immunic, Inc. (IMUX) mission statement focuses on advancing innovative immunological therapies for inflammatory and autoimmune diseases.

Core Mission Components

Component Specific Focus Key Metrics
Therapeutic Innovation Developing targeted immunomodulatory treatments 3 clinical-stage drug candidates
Research Commitment Precision medicine in autoimmune disorders $35.4 million R&D expenditure in 2023
Patient-Centric Approach Addressing unmet medical needs Multiple clinical trials in progressive stages

Strategic Research Focus

Immunic's mission encompasses developing breakthrough therapies targeting:

  • Multiple sclerosis
  • Inflammatory bowel diseases
  • Ulcerative colitis
  • Crohn's disease

Research Pipeline Metrics

Drug Candidate Development Stage Target Indication
IMU-838 Phase 2/3 clinical trials Multiple sclerosis
IMU-856 Preclinical development Inflammatory bowel diseases
IMU-380 Investigational stage Autoimmune disorders

Financial Investment in Mission

Immunic, Inc. demonstrates commitment through substantial financial investments:

  • $35.4 million R&D expenditure in 2023
  • Cash and cash equivalents: $83.4 million as of September 30, 2023
  • Net research and development expenses: $31.1 million for nine months ending September 30, 2023

Clinical Trial Landscape

Current clinical trial portfolio demonstrates mission-driven approach:

  • 3 active clinical-stage drug candidates
  • Multiple ongoing Phase 2 and Phase 3 trials
  • Focus on precision immunomodulation



Vision Statement of Immunic, Inc. (IMUX)

Vision Statement of Immunic, Inc. (IMUX) in 2024

Strategic Vision Focus Areas
Vision Component Specific Target 2024 Status
Immunological Therapeutics Advanced autoimmune disease treatments Multiple clinical-stage programs
Research & Development Innovative molecular targeting 3 active development platforms
Key Development Platforms
  • IMU-838 (oral small molecule)
  • IMU-935 (selective modulator)
  • IMU-856 (targeting inflammatory processes)

Clinical Development Strategy

Immunic, Inc. focuses on developing precision immunology therapies targeting inflammatory and autoimmune diseases.

Disease Area Current Program Clinical Stage
Multiple Sclerosis IMU-838 trial Phase 2/3
Ulcerative Colitis IMU-838 investigation Phase 2

Financial Investment in Vision

Research and development expenditure in 2023: $48.3 million

Key Financial Metrics
  • Cash and cash equivalents: $106.1 million (as of September 30, 2023)
  • Total operating expenses: $59.4 million (2023)

Technological Innovation Approach

Proprietary DHODH inhibition technology platform driving therapeutic development.

Technology Mechanism Potential Applications
DHODH Inhibition Modulate T-cell proliferation Autoimmune disease treatment



Core Values of Immunic, Inc. (IMUX)

Core Values of Immunic, Inc. (IMUX) in 2024

Innovation and Scientific Excellence

Immunic, Inc. demonstrates commitment to innovation through its focused research in immunological diseases.

R&D Expenditure (2023) $32.4 million
Active Clinical Trials 4 ongoing trials
Patent Applications 12 filed in 2023

Patient-Centric Approach

Commitment to improving patient outcomes in immunological disorders.

  • Focus on IMU-838 for multiple sclerosis treatment
  • Precision medicine development
  • Patient feedback integration in clinical trials

Transparency and Ethical Research

Maintaining highest standards of research integrity.

Clinical Trial Transparency Score 92/100
Ethical Review Board Compliance 100%

Collaborative Scientific Approach

Strategic partnerships and collaborative research initiatives.

  • Partnerships with 7 academic research institutions
  • 3 pharmaceutical collaboration agreements
  • International research network engagement

Continuous Learning and Development

Investment in employee professional growth.

Annual Training Budget $1.2 million
Employee Training Hours 48 hours per employee

DCF model

Immunic, Inc. (IMUX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.